Artrya (AYA) is held by 9 ASX ETFs. Over all time it rose 983.3%: on $10,000, +$98333. We explain 14 big moves in that time.
About AYA
- SectorHealth Care
- IndustryHealth Care Equipment & Services
- Size$560.6m
- Held by9 ETFs
- Big moves14 in all time
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +9.3%2 Oct 2026· Contract
Artrya signed a five-year commercial agreement with Huntsville Hospital Health System for its Salix AI cardiac imaging product, driving a ~9% share price gain.
- +8.2%18 Sep 2026· Operational
Artrya's shares surged on exceptionally high volume likely driven by growing investor interest in its AI cardiac imaging commercialisation progress, amplified by multiple media mentions and analyst coverage in the days prior.
- −16.7%10 Sep 2026· Stake Change
A substantial holder (Regal Partners) reduced its stake in Artrya to 9.97%, triggering a sharp sell-off as the market interpreted the institutional exit as a negative signal.
- −16.4%30 Jul 2026· Operational
A quarterly activity report or operational update released around 29 July 2026 disappointed investors, causing the stock to sell off sharply despite no broader sector weakness driving the move.
- +7.7%23 Jun 2026· Sector Flow
Artrya's stock rose significantly on renewed investor interest in its AI-powered cardiac imaging technology and its US market expansion efforts, placing it in the spotlight as a hot AI healthcare theme.
- +6.2%29 May 2026· Sector Flow
No direct news article specific to Artrya Limited was found near the event date; the price move may be related to broader ASX healthcare sector flows.
- +6.5%19 Dec 2025· Unknown
Insufficient evidence to determine the cause of the price movement.
- −8.2%19 Nov 2025· Unknown
No specific cause identified; the abnormal price decline for Artrya Limited on 2025-11-18 lacks direct news or announcement support.
- −11.5%18 Nov 2025· Unknown
No specific news was found; the price drop likely reflects an unannounced operational or market event.
- +9.3%23 Oct 2025· Unknown
No direct news explains ARTRYA LIMITED's abnormal price move on 2025-10-22.
- +7.2%3 Sep 2025· Unknown
Insufficient evidence to determine the cause of the price movement.
- +11.7%22 Aug 2025· Regulatory
Artrya received FDA clearance for its Salix Coronary Plaque Module, boosting investor confidence.
- +37.7%21 Aug 2025· Regulatory
Artrya received FDA clearance for its Salix Coronary Plaque Module, driving a significant share price surge.
- +8.8%28 Mar 2025· Unknown
No identifiable news or announcement explains the abnormal price movement for Artrya Limited on 2025-03-27.
Held by 9 ETFs
Of every $10,000 in each fund, how much is in AYA today.
- XMETBetaShares Energy Transition Metals ETF$3693.69%
- SLVMGlobal X Silver Miners ETF$2312.31%
- MNRSBetaShares Global Gold Miners Currency Hedged ETF$660.66%
- ATECBETASHARES S&P/ASX AUSTRALIAN TECHNOLOGY ETF$470.47%
- GDXVanEck Gold Miners ETF$400.40%
- SSOSTATE STREET SPDR S&P/ASX SMALL ORDINARIES ETF$180.18%
- ISOiShares S&P/ASX Small Ordinaries ETF$180.18%
- VISMVanguard MSCI International Small Companies Index ETF$3.520.04%
- VASVanguard Australian Shares Index ETF$1.380.01%
Why did AYA rise 37.7% on 21 Aug 2025?
Artrya
Artrya received FDA clearance for its Salix Coronary Plaque Module, driving a significant share price surge.
The price move on 2025-08-21 aligns with the news of FDA clearance for Artrya's Salix Coronary Plaque Module, a major regulatory milestone that directly impacts the company's commercial prospects. The announcement is the only substantive news around the event date and explains the large abnormal move.
General information only, not personal advice — prepared without regard to your objectives, financial situation or needs. Past performance is not indicative of future performance.
Evidence
News coverage
What it did to the 9 ETFs holding AYA
On $10,000 in each fund, at the weight it holds today